Drugs / Sintilimal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05563012 | Sep 2022 → Oct 2025 overdue | — | Renmin Hospital of Wuhan University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sintilimal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05563012 ↗ |
| Known as | Sintilimal Injection | “Drug: Sintilimal Injection” NCT05563012 ↗ |
| Action | Inhibit | “sintilimab (PD1 inhibitor)” NCT05563012 ↗ |
| Route | Intravenous | “will be given i.v.” NCT05563012 ↗ |